Is Antisense Therapeutics Limited (ATHJF) a Buy, Sell, or Hold?
OTC : ATHJF
Antisense Therapeutics Limited
$0.012 USD
-$0.04 (-76.0%)
- Volume
- 2.5K
- Average Volume
- 390
- Market Capitalization
- $19.64M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $0.08
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
OTC
James Garner MBA
Drug Manufacturers - Specialty & Generic
Healthcare
ATHJF
N/A
AU
USD
Liquidity Metrics
Sales & Valuation
$2.97M
Profitability
-$0.0135
-$11.92M
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-10.76
3/9
$9.32M
$14.53M
$5.17M
-$23.29M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Cathryn Clary | Chief Medical Advisor |
| Anthony Filippis | Chief Operating Officer |
| James Garner | Chief Executive Officer, MD & Director |
| Deborah Ambrosini | Company Secretary & Chief Financial Officer |
| Alicia Mellors | Joint Company Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Antisense Therapeutics Limited (OTC:ATHJF) Stock
Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory conditions, such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. The company's second candidate, ATL1103, is an advanced second-generation antisense medication. This drug works by blocking growth hormone receptor expression, which subsequently lowers levels of insulin-like growth factor-I (IGF-I) in the bloodstream, and has successfully completed Phase II clinical trials for diseases linked to excessive growth hormone activity. Antisens ... e Therapeutics Limited was established in 2000 and operates from its base in Toorak, Australia.
Frequently Asked Questions
-
What is the current Antisense Therapeutics Limited (ATHJF) stock price?
-
Antisense Therapeutics Limited(OTC:ATHJF) stock price is $0.012 in the last trading session. During the trading session, ATHJF stock reached the peak price of $0.075 while $0.01 was the lowest point it dropped to. The percentage change in ATHJF stock occurred in the recent session was --76.0% while the dollar amount for the price change in ATHJF stock was -$0.04.
-
ATHJF's industry and sector of operation?
-
The OTC listed ATHJF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ATHJF?
-
Cathryn Clary | Chief Medical Advisor
Anthony Filippis | Chief Operating Officer
James Garner | Chief Executive Officer, MD & Director
Deborah Ambrosini | Company Secretary & Chief Financial Officer
Alicia Mellors | Joint Company Secretary -
How many employees does ATHJF have?
-
Number of ATHJF employees currently stands at None. ATHJF operates from 14 Wallace Avenue, Toorak, VIC 3142, AU.
-
Link for ATHJF official website?
-
Official Website of ATHJF is: https://www.antisense.com.au
-
How do I contact ATHJF?
-
ATHJF could be contacted at phone #61 3 9827 8999 and can also be accessed through its website. ATHJF operates from 14 Wallace Avenue, Toorak, VIC 3142, AU.
-
How many shares of ATHJF are traded daily?
-
The average number of ATHJF shares traded daily for last 3 months was 390.
-
What is the market cap of ATHJF currently?
-
The market value of ATHJF currently stands at $19.64M with its latest stock price at $0.012